E-resources
Peer reviewed
Open access
-
No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccinesYalcinkaya, Ahmet; Cavalli, Marco; Cederholm, Axel; Aranda-Guillén, Maribel; Behere, Anish; Mildner, Hedvig; Lakshmikanth, Tadepally; Gonzalez, Laura; Mugabo, Constantin Habimana; Johnsson, Anette; Ekwall, Olov; Kämpe, Olle; Bensing, Sophie; Brodin, Petter; Hallberg, Pär; Wadelius, Mia; Landegren, Nils
npj vaccines, 2024, Volume: 9, Issue: 1Journal Article
Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.
